Oculocutaneous albinism (OCA) is a group of autosomal recessive disorders characterized by defective melanin biosynthesis, which results in congenital hypopigmentation of the hair, skin, and eyes despite a normal melanocyte number. Co-occurrence of malignant melanoma (MM) is considered rare in patients with OCA, compared with that of non-melanoma skin cancer, such as squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). Although around half of cases of MM in patients with OCA have been reported to be melanotic, the mechanisms of developing pigmented MM remains unclear. We report here a patient with OCA type 4 (OCA4) who presented with a melanotic MM, in which tumour cells showed high expression of microphthalmia-associated transcription factor (MITF).

CASE REPORT
A 66-year-old Japanese man presented with a 6-month history of an enlarging black nodule on his back. Since birth, he had exhibited light yellow hair and hypomelanotic eyes and skin. He recalled experiencing sunburn during childhood, but had avoided sun exposure in older years. His parents were not consanguineous or affected by albinism, but his sister shared the same physical characteristics. On physical examination, the patient had hypomelanotic skin, gray-white irides, and bilateral horizontal nystagmus. His hair was dyed black. On his back was a black, firm, well-defined, irregularly-shaped tumour, 50×25 mm in size (Fig. 1). Systemic and laboratory examinations were normal. A melanoma was suspected, and excisional biopsy of the lesion was taken with 0.5-cm margins.

Histological examination revealed a superficial spreading MM (Fig. S1 a, b). Melanin pigments were detected in some of these cells. Breslow thickness was 4.2 mm (Clark’s level IV). The patient subsequently underwent local re-excision with additional 2-cm margins and sentinel node biopsy, which was negative. A whole-body scan with positron emission tomography and computed tomography showed no evidence of metastatic lesions. The final staging of the patient was T4bN0M0 (Stage IIC).

Immunohistochemical examination demonstrated stronger reactivity of tumour cells to antibodies against MITF (Atlas Antibodies, Stockholm, Sweden), tyrosinase (TYR) (Cell Signaling Technology, Danvers, MA, USA), tyrosinase-related protein 1 (TRP1) (Novocastra, Newcastle upon Tyne, UK), and tyrosinase-related protein 2 (TRP2) (Abcam, Cambridge, MA, USA) than that of normal epidermal melanocytes (Fig. S1 c-h), as well as positivity to DOPA reaction (Sigma-Aldrich, Saint Louis, USA) (not shown), albeit with some heterogeneity among the tumour cells.

Genetic blood testing gave a diagnosis of OCA4, as the patient had 2 heterozygous mutations in \( SLC45A2 \) (p.P78L and p.D157N) (Fig. 2). Further testing with MM cells showed no change in mutations in \( SLC45A2 \), indicating no recovery of gene mutation in MM. Mutation of \( BRAF \) p.V600E was detected, and no \( NRAS \) (exon 2) or \( KIT \) (exon 9, 11, 13, 17, and 18) mutations were found.

Postoperative adjuvant chemotherapy consisted of 3 courses of DAV-Feron immunochemotherapy (dacarbazine, nimustine hydrochloride, vincristine, interferon (INF)-β) and subsequent monthly local injection of INF-β. However, bone and lymph node metastases developed, and the patient died approximately 19 months after his initial visit.
DISCUSSION

OCA is classified into 2 types: non-syndromic and syndromic, with non-syndromic further subdivided into 7 forms based on clinical and genetic findings (1). OCA types 1 (OCA1) and 2 account for approximately 40% and 50% of OCA cases, respectively, while OCA4 is rare worldwide (2). However, OCA4 is the second-most common type following OCA1 in Far-East Asian populations, particularly among the Japanese, with a prevalence of 24–27% (2, 3). OCA4 is caused by mutations in the *SLC45A2* gene (4). The SLC45A2 protein, which contains 12 putative transmembrane domains, is expressed only in melanocytes and may function as a membrane transporter in melanosomes (5). *p.D157N*, a mutation also detected in the present case, is the most common mutant allele in Japanese OCA4 patients, with an allele frequency of 0.39, and confers very low functional activity in melanogenesis (2). *p.P78L*, the other mutation, was a novel mutation. Okamura et al. (1) reported this result in 2014 and suggested that this mutation resulted in the loss of melanogenesis activity.

The majority of cutaneous malignancies in OCA are SCC (75–88%), with BCC (9–23%) being less common, while MM is rare (1.3–3%) (6, 7). To our knowledge, while 33 cases of MM in patients with OCA have been reported in the English literature, 23 cases of cutaneous malignancies with OCA were reported in the Japanese literature, of which 10 cases (43%) were MM, followed by SCC and BCC in 8 (34%) and 7 (30%) cases, respectively. As many cases may be unreported, a cohort study of OCA patients is required for the correct relative frequencies in Japan. To our knowledge, this is the first case with melanotic MM in OCA4.

Amelanotic and melanotic MM were reported at the same frequency in cases of OCA. All cases of MM with OCA presenting with the absence of tyrosinase activity, usually type 1a, were amelanotic MM. However, other types of OCA with normal or weak tyrosinase activity can develop both melanotic MM as well as amelanotic MM. In OCA4 melanocytes, tyrosinase activity is reduced due to disruption of tyrosinase processing and intracellular trafficking to the melanosomes, and the enzyme is abnormally secreted from the cells in immature melano-